ClinicalTrials.gg
RecruitingNCT07435168CHEST-CAUpdated Feb 27, 2026

CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis

An interventional study of Screening thourgh examinations including bonescintigraphy in Cardiac Amyloidosis and Chest Pain, sponsored by Rigshospitalet, Denmark. Recruiting at 1 site in Denmark. Open to male participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
65 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Amyloid Neuropathies, Familial with a site in Denmark — 6 open to participants now, 7 under way, 2 of them phase 3. Amyloid Neuropathies, Familial · Denmark.

Started
2024
with 1 other
No phase
5 of 11
2 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Rigshospitalet, Denmark

Among the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark, this one is one of 2 that started in 2024, is one of 5 with no phase, and was the 9th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

6 of the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Amyloid Neuropathies, Familial with a site in Denmark, or all of them as a file.
02

Study summary

The objective of this observational, prospective study is to determine the prevalence of Cardiac Amyloidosis (CA) in males over the age of 65 who experience chest pain but show no signs of coronary artery disease (CAD).

Prior to inclusion, all patients will have undergone a CT coronary angiogram or an Rb-PET scan to rule out the possibility of CAD.

Participants will be subject to several examinations, including blood tests, urine samples, ECG, echocardiography, and bone scintigraphy. An endomyocardial biopsy may be conducted if necessary.

03

Conditions studied

  • Cardiac Amyloidosis
  • Chest Pain
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

No signs of CAD through Rb-PET and/or CT coronary arteriogram

Exclusion criteria

Exclusion Criteria:

Previous history of amyloidosis

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Other
    Interventional group

    Other: Screening thourgh examinations including bonescintigraphy

Interventions

  • OtherScreening thourgh examinations including bonescintigraphy

    Clinical examination, blood samples, echo, bone scintigraphy

06

What researchers measure

Primary outcomes

  1. Prevalence of ATTR-CA in patients experiencing chest pain

    Time frame: Up to 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.

Of 30 interventional studies with no phase under Amyloid Neuropathies, Familial, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 67. This study's planned 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Feb 27, 2026
StartActual
Apr 1, 2024
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07435168
Responsible party
Emil Loldrup Fosbol (MD, Professor, Consultant Cardiologist, DMSc, Rigshospitalet, Denmark) — Principal investigator
First posted
Feb 27, 2026
Start date
Apr 1, 2024
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Navid Noory, MD
Contact
navid.noory@regionh.dk
4535453108

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion